Biomatics Capital Partners

What is Biomatics Capital Partners?

Biomatics Capital Partners is a Seattle-based investment firm that specializes in healthcare and life sciences, focusing particularly on early-stage investments within these sectors. The fund, reported to have $200 million in capital, centers its investment thesis on transformative healthcare innovations, especially in the realms of genomics and digital health. Since its establishment, the firm has sought to be at the forefront of the rapidly converging fields of genomics and digital data, which hold the potential to develop superior therapeutics, diagnostics, and delivery models.

This convergence is seen as a driving force in transforming medicine into a value-based healthcare system that promises lower costs and better patient outcomes.

Biomatics Capital Partners operates with a minim investment threshold of $7,800,000 and a maximum investment cap of $217,000,000, engaging with ventures that are breaking new ground in science and technology to create the next generation of companies leading the charge in healthcare reform.

Co-founders and General Partners Dr.

Boris Nikolic and Julie Sunderland have been investing together since 2010, bringing to bear their extensive technical knowledge, partnering expertise, and a rich network of relationships including leading academics, pharmaceutical executives, and venture capital firms.

Beyond financial investment, Biomatics prides itself on providing deep strategic and operational support to their portfolio companies, helping to refine business models, develop comprehensive R&D plans, formulate investor presentations, and facilitate introductions to high-caliber investors.

Their hands-on approach has earned endorsements from industry leaders, who celebrate Biomatics's savvy team and their value-add collaborations characterized by keen scientific and business insights, a commitment to supporting companies’ success trajectories, and nurturing long-term relationships built on genuine partnership and shared ambition for large-scale impact on healthcare.

What they say:

We are a venture firm focused on these interconnected sectors.

What we look for: We invest in health care, life science, and biotechnology ventures.